Gentisic acid prevents the transition from pressure overload-induced cardiac hypertrophy to heart failure

Abstract

We previously reported that gentisic acid attenuates cardiac hypertrophy and fibrosis in transverse aortic constriction (TAC)-induced cardiac hypertrophy. Here, we examined whether gentisic acid prevents the development of heart failure. Heart failure was induced in mice via chronic TAC. Mice were administered the vehicle, gentisic acid (10 and 100 mg∙kg −1 ∙day −1 ), or bisoprolol (0.5 mg∙kg −1 ∙day −1 ) orally for 3 weeks, beginning 3 weeks after TAC. After oral administration of gentisic acid (2000 mg∙kg −1 ), no significant differences in organ weight, histology, or analyzed serum and hematological parameters were observed between female mice in the control and gentisic acid-treated groups. Gentisic acid administration inhibited cardiac dysfunction in a dose-dependent manner, and reduced cardiac hypertrophy and fibrosis, as was revealed via western blotting, quantitative real-time PCR, and Masson’s trichrome staining. Gentisic acid dose-dependently reduced the expression of fibrosis marker genes, suppressed the renin-angiotensin-aldosterone system, and reduced lung size and pulmonary vascular remodeling. Our data indicate that gentisic acid prevents cardiac hypertrophy, fibrosis, cardiac dysfunction, and pulmonary pathology in TAC-induced heart failure. These findings suggest that supplementation with gentisic acid may provide an advantage in preventing the progression from cardiac hypertrophy to heart failure.

A review on gentisic acid as a plant derived phenolic acid and metabolite of aspirin: Comprehensive pharmacology, toxicology, and some pharmaceutical aspects

“…In another study of Sun et al (2019), it was demonstrated that GA also prevents the development of heart failure, which induced in mice via chronic transverse aortic constriction. GA (10 and 100 mgÁkgÁday) administrated orally for 3 weeks, beginning 3 weeks after induction model of heart failure.…”

“…Results showed that GA through the block of the renin-angiotensin-aldosterone system and reduction the expression of fibrosis marker genes, significantly and dosedependently inhibited cardiac dysfunction and decreased cardiac hypertrophy and fibrosis. GA also reduced lung size and pulmonary vascular remodeling (Sun et al, 2019).…”

Versatile Applications of Cyanobacteria in Biotechnology

“…Phenolic acids produced by cyanobacteria with great scavenging of free radicals and detoxification of reactive oxygen species (ROS) facilitated their relevance as therapeutic agents. For instance, anti-winkle and skin whitening facilitated by ferulic acids [42], antiaging effect facilitated by gallic acids [43], effective heart failure recovery facilitated by syringic, gentisic and gallic acids [44], as well as antimicrobial effects of other phenolic compounds were generated by cyanobacteria [45][46][47].…”

Bioactive Metabolites Produced by Cyanobacteria for Growth Adaptation and Their Pharmacological Properties

“…As with other phenolic compounds, many studies identified that plant phenolic acids also manifest antimicrobial [185] and antiviral properties [186]. Due to their ability to reduce oxidative damage or stress in cells, phenolic acids such as gentisic acid, gallic acid and syringic acid exhibitgood recovery in heart failure [187], memory loss [188] and wound healing [189], respectively. Previous studies have also reported that ferulic acids can produce skin whitening and anti-wrinkle effects [190] whereas gallic acid has antiaging properties [191].…”